akamis-bio
(2)
John Beadle and the business of starting again
A sale to Pfizer, a merger that created PsiOxus, and a second act in the boardroom. John Beadle’s career follows the work that begins after an idea has found its first believers.
Howard Davis
Howard Davis, Ph.D., is the CEO of Akamis Bio, a clinical-stage oncology company in Cambridge, Massachusetts building tumor gene therapies on its proprietary T-SIGn platform. A chemical engineer turned biomedical engineer, he spent two decades moving between Boston Consulting Group, Novartis, Biogen, Flagship Pioneering and Atlas Venture before taking the top job at the company once known as PsiOxus. His current mission: prove that an adenoviral therapy delivered through a vein - not a needle into the tumor - can reach metastatic cancer the body has hidden, and turn those tumors against themselves.